New onset of diabetes mellitus and weight loss as a manifestation of pancreatic cancer
Authors:
Aleš Dvořák; Miroslav Souček
Authors place of work:
II. interní klinika, Fakultní nemocnice u sv. Anny v Brně
Published in the journal:
Vnitř Lék 2022; 68(E-6): 23-27
Category:
Case reports
doi:
https://doi.org/10.36290/vnl.2022.087
Summary
The case report is about a 68-years-old man who developed a weight loss and diabetes mellitus as early symptoms of pancreatic cancer several months before the diagnosis. Unfortunately, the diagnosis was made too late, at the stage of generalized disease, when symptomatic treatment was the only possible way. The aim of the article is to warn about this possible way of pancreatic cancer manifestation, because only the diagnosis determined in time, when the tumor is localized, allows its resection - the only curative treatment method. For this reason, it is necessary to consider the presence of pancreatic cancer in the case of an atypical manifestation of diabetes.
Keywords:
Weight loss – Pancreatic cancer – diabetes mellitus
Zdroje
1. Češka R et al. Interna 3. vydání. Praha/Kroměříž: Triton 2020, 964 stran. ISBN 978-80-7553-782-9
2. Frič P, Šedo A, Škrha J et al. Early detection of sporadic pancreatic cancer: time for change. Eur J Gastroenterol Hepatol. 2017 Aug;29(8):885-891.
3. Škrha J., Frič P., Bušek P. et al., Sporadic Pancreatic Cancer: Glucose Homeostasis and Pancreatogenic Type 3 Diabetes, in Advances in Pancreatic Cancer. London, United Kingdom: IntechOpen, 2018
4. Škrha P., Diabetes mellitus a karcinom pankreatu – příčina nebo následek? Vnitř Lék 2014; 60(9): 787–790.
5. Dušek L, Mužík J, Kubásek M et at. Epidemiologie zhoubných nádorů v České republice. [cit. 2022-6-10]. Dostupný z WWW: http://www.svod.cz.
6. McGuigan A, Kelly P, Turkington RC et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov 21;24(43):4846-4861.
7. Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018 May 21;24(19)2047-2060.
8. Mueller AM, Meier CR, Jick SS et al. Characterization of the deterioration of diabetes control in patients with a subsequent diagnosis of pancreatic cancer: A descriptive study. Pancreatology. 2022 Apr;22(3):387-395.
9. Loveday BPT, Lipton L, Thomson BN. Pancreatic cancer: An update on diagnosis and management. Aust J Gen Pract. 2019 Dec;48(12):826-831.
10. Tempero MA. NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019 May 1;17(5.5):603-605.
11. Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020 Oct;50(10):1117-1125.
12. Zhu H, Wei M, Xu J et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020 Mar 2;19(1):49.
13. Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer. 2018 Jun;4(6):418-428.
14. Ren B, Cui M, Yang G et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018 Jul 30;17(1):108.
15. Sharma A, Kandlakunta H, Nagpal SJS et al. Model to Determine Risk of Pancreatic Cancer in Patients With New‑Onset Diabetes. Gastroenterology. 2018 Sep;155(3):730-739.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2022 Číslo E-6
Najčítanejšie v tomto čísle
- Clinical experience with the use of newer antibiotics in internal medicine
- Evaluation of medication errors in the hospital environment
- Therapy of immunoglonuline IgG4 related disease (IgG4-RD)
- New onset of diabetes mellitus and weight loss as a manifestation of pancreatic cancer